Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Equity: 2021-2025

Historic Return on Equity for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to 0.77%.

  • Silence Therapeutics' Return on Equity was N/A to 0.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77%, marking a year-over-year change of. This contributed to the annual value of 0.58% for FY2024, which is 162.00% up from last year.
  • Latest data reveals that Silence Therapeutics reported Return on Equity of 0.77% as of Q3 2025, which was down 0.32% from 0.76% recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' Return on Equity peaked at 0.59% during Q1 2024, and registered a low of 7.40% during Q1 2022.
  • In the last 3 years, Silence Therapeutics' Return on Equity had a median value of 0.75% in 2025 and averaged 1.03%.
  • As far as peak fluctuations go, Silence Therapeutics' Return on Equity soared by 476bps in 2023, and later dropped by 14bps in 2025.
  • MRQ analysis of 5 years shows Silence Therapeutics' Return on Equity stood at 3.71% in 2021, then tumbled by 100bps to 7.40% in 2022, then surged by 64bps to 2.65% in 2023, then skyrocketed by 76bps to 0.65% in 2024, then fell by 18bps to 0.77% in 2025.
  • Its Return on Equity stands at 0.77% for Q3 2025, versus 0.76% for Q2 2025 and 0.74% for Q1 2025.